Cargando…
Pharmacological inhibition of EZH2 combined with DNA-damaging agents interferes with the DNA damage response in MM cells
Enhancer of zeste homolog 2 (EZH2) serves a pivotal role in epigenetic silencing by acting as a histone methyltransferase. It has been confirmed that EZH2 overexpression occurs in different types of cancer and is involved in drug resistance, while it remains unclear how a DNA-damaging event may prom...
Autores principales: | Xu, Li, Tang, Hailong, Wang, Kai, Zheng, Yanhua, Feng, Juan, Dong, Hongjuan, Jin, Yulong, Cao, Chun, Chen, Xiequn, Gao, Guangxun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471932/ https://www.ncbi.nlm.nih.gov/pubmed/30942459 http://dx.doi.org/10.3892/mmr.2019.10075 |
Ejemplares similares
-
Pharmacologic Tumor PDL1 Depletion with Cefepime or Ceftazidime Promotes DNA Damage and Sensitivity to DNA-Damaging Agents
por: Murray, Clare, et al.
Publicado: (2022) -
Pharmacological boost of DNA damage response and repair by enhanced biogenesis of DNA damage response RNAs
por: Gioia, Ubaldo, et al.
Publicado: (2019) -
Combating resistance to DNA damaging agents
por: Choi, Jung-Suk, et al.
Publicado: (2018) -
DNA damaging agents in ovarian cancer
por: Barretina-Ginesta, Maria-Pilar
Publicado: (2020) -
Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials
por: Zheng, Yanhua, et al.
Publicado: (2018)